RPT1G is the first well-tolerated NAMPT inhibitor, demonstrating safety in healthy volunteers at single and multiple ascending dose levels.Target ...

Race Oncology has discovered the unique molecular mechanism of action for its RC220 therapy, opening two new major potential ...

Myeloid malignancies are a manifestation of clonal expansion of hematopoietic cells driven by somatic genetic alterations that may arise in a potential background of deleterious germline variants. As ...

Artificial intelligence may be leveraged to improve minimal residual disease measurements for patients. A new review outlines the role of minimal residual disease (MRD) assessments via blood component ...

Race Oncology Ltd. ( ($AU:RAC) ) has issued an update. Race Oncology Ltd has announced the initiation of new clinical trials for their drug RC220 ...

Distrust in the End-of-Life Care Provided to a Parent and Long-Term Negative Outcomes Among Bereaved Adolescents: A Population-Based Survey Study The impact of pretransplant VitD status on overall ...

A myeloid panel mutation analysis should be prioritized for patients with clonal cytopenia of undetermined significance (CCUS) as it can better assess patient risks for progression to a myeloid ...

Trained Therapeutix, Inc., a biotech company training immunity at its origin with nanomedicines, today announced preclinical data on RIDE-001, ...